{"id":"W4399012115","doi":"10.1038/s41591-024-03015-5","title":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","year":2024,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":197,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Medical Research Council; Eli Lilly Japan; Mitsubishi Tanabe Pharma Corporation; Relypsa; Teijin Pharma; Shionogi; Novo Nordisk; Bayer HealthCare; Intercept Pharmaceuticals; National Institutes of Health; Mylan; Astellas Pharma; FibroGen; MannKind Corporation; CSL Behring; National Institute for Health and Care Research; ReCor Medical; Intarcia Therapeutics; Boehringer Ingelheim Japan; Public Health England; McMaster University; Esperion Therapeutics; Alnylam Pharmaceuticals; British Heart Foundation; Brigham and Women's Hospital; Novartis Pharma; European Commission; Kowa Company; Sanofi; GlaxoSmithKline; Novo Nordisk Pharma; Amgen; Pfizer; Bayer Yakuhin; Celgene; AstraZeneca; Ono Pharmaceutical; Eli Lilly and Company; Akebia Therapeutics; Bristol-Myers Squibb","keywords":"Semaglutide; Medicine; Disease; Obesity; Term (time); Internal medicine; Kidney disease; Intensive care medicine; Diabetes mellitus; Type 2 diabetes; Endocrinology; Liraglutide","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001194974,0.000447331,0.001167023,0.0001406576,0.0001586587,0.0006212993,0.0001557263,0.0005348939,0.00216883],"category_scores_gemma":[0.001112528,0.0001148529,0.001192485,0.0001949988,0.000280516,0.0003789781,0.0002667865,0.00100014,0.0001776169],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001640729,"about_ca_system_score_gemma":0.0002829506,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003002014,"about_ca_topic_score_gemma":0.001001809,"domain_scores_codex":[0.9996098,0.0002477975,0.00002516415,0.00003302876,0.00004350485,0.00004080515],"domain_scores_gemma":[0.9992636,0.0002607884,0.0002138224,0.00003453131,0.00004471856,0.0001826377],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.915083,0.001773194,0.0292854,0.001845065,0.004971171,0.0001636247,0.00005923078,0.00147376,0.004013726,0.0004871962,0.003136525,0.0377081],"study_design_scores_gemma":[0.6230291,0.1596553,0.1821483,0.0009416163,0.01335324,0.0008239463,0.0002216696,0.005302511,0.003951766,0.002082522,0.008393095,0.00009707321],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9849682,0.01120448,0.000391746,0.0005717967,0.0001954525,0.0001436746,0.000750709,0.00003455543,0.001739322],"genre_scores_gemma":[0.9935481,0.002737274,0.0003760651,0.0005909501,0.000441893,0.0002515845,0.0009513056,0.000005828778,0.00109701],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00216883,"threshold_uncertainty_score":0.007255495,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009524700846208177,"score_gpt":0.2818829617407348,"score_spread":0.2723582608945266,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}